Research review / The evidence
The Melanotan 2 Research Record, Read Finding by Finding
Small controlled human pilots, a deep rodent mechanism literature, and a growing file of safety case reports. What each tier of evidence can and cannot carry.
Before the details
The Melanotan 2 research splits cleanly into three tiers, and reading it well means keeping them apart. The first is small but controlled: two human pilot studies, one on tanning and one on erections, each with a placebo comparison but only a handful of subjects. The second is large and consistent but in animals: dozens of rodent studies on appetite, energy, and erection that map the receptor biology in detail. The third is anecdotal in form but serious in content: published case reports of harm in real users.
The rule of thumb: the human pilots show the effects are real in people; the animal work explains how; the case reports flag what can go wrong. None of it adds up to a completed efficacy or safety trial — there isn't one. The Melanotan 2 tanning effect is well documented, but tanning is the easy part of the story; the rest needs this much care.
The human pilot data
In a single-blind, alternating-day, placebo-controlled pilot Phase I study, 3 healthy men received subcutaneous Melanotan 2 escalated from 0.01 to 0.025-0.03 mg/kg, dosed every other weekday for two weeks [1]. Pigmentation of the face, upper body, and buttocks increased in 2 of 3 subjects after only five low doses, with no UV exposure; the study also recorded spontaneous penile erections lasting one to five hours, mild nausea, and dose-limiting somnolence at the top dose [1]. The recommended single dose for future Phase I work was 0.025 mg/kg/day. These are study-design facts from a published trial, not a dosing recommendation, and Melanotan 2 is not approved for human use.
The erectile finding was tested directly. In a double-blind, placebo-controlled crossover study of 10 men with psychogenic erectile dysfunction, subcutaneous Melanotan 2 (0.025 mg/kg) produced clinically apparent erections in 8 of 10 men; mean duration of greater than 80% tip rigidity was 38.0 minutes with the peptide versus 3.0 minutes with placebo (p=0.0045), with transient nausea, stretching, and yawning that required no treatment [2]. Together these two small studies are the complete controlled human record — there is no completed Phase II or Phase III trial [1][2].
The mechanism and appetite literature
The rodent record is where the receptor biology is worked out. In mice, intraperitoneal Melanotan 2 raised metabolic rate and reduced food intake in wild-type animals, while MC4-receptor knockout mice were insensitive to both — establishing MC4R as the mediator of these acute responses, with little MC3R contribution [10]. Site-specific work localized part of the appetite effect: bilateral microinjection of Melanotan 2 (0.1-1 nmol per side) into the nucleus accumbens decreased both food consumption and the motivation to work for food, without taste aversion or a change in metabolic rate [5].
The central pharmacology extends further. A receptor-conformation study found Melanotan 2 and a close analog had lower MC3R affinity and that mutating Tyr268 in MC4R reduced binding, supporting the idea that selectivity is governed by how the cyclic core is presented to each receptor [12]. In rats, chronic intracerebroventricular Melanotan 2 modulated dopamine-receptor binding across reward-related regions including the nucleus accumbens and striatum, linking sustained melanocortin agonism to central dopaminergic activity [13]. A bioanalytical study developed a solid-phase-extraction plus reversed-phase HPLC method to isolate and quantify the peptide from rabbit urine, with linear curves from 0.1 to 4.0 micrograms/ml — the kind of assay groundwork the field was built on [7].
Tanning, pigmentation, and the eumelanin pathway
The Melanotan 2 tanning effect is the most directly demonstrated property: the 1996 human pilot showed measurable pigmentation without UV [1], and the mechanism is the MC1R-cAMP-MITF cascade that shifts melanin synthesis toward photoprotective eumelanin [11]. The 2008 total synthesis explicitly characterizes Melanotan 2 as a cyclic heptapeptide that stimulates the skin-tanning (melanogenesis) process, completing the synthesis in 12 steps at 2.6% overall yield [15]. The persistence of the tan after the peptide clears is a downstream feature of continued melanin synthesis, not of the molecule lingering [9].
The pigmentation pathway is also the source of the gravest concern. Because MC1R agonism drives melanocyte activity broadly, the same biology that darkens skin can darken and change moles and appears to promote new ones — documented in the eruptive-nevi and dermoscopy case literature and discussed in full on the effects page [16][20][21].
The safety case-report file
The harm literature is built from case reports, which establish that an event happened in association with use — not how often it happens. A nephrology case report with literature review attributes renal infarction to Melanotan 2 and notes that rhabdomyolysis with renal failure had been described previously, proposing thrombotic and direct-toxic renal mechanisms [4]. A separate case links injection to systemic toxicity with rhabdomyolysis [17]. Priapism is reported repeatedly, including after apparent overdose [18][19][24], and posterior reversible encephalopathy syndrome has been described in one report [23].
The pigmented-lesion file is the largest: eruptive dysplastic nevi [16], changes in melanocytic lesions on dermoscopy [21], darkening and eruption of nevi within a day of a single dose [20], and melanoma and melanoma in situ in users [25][26]. A 2026 case documented reversible oral-mucosal pigmentation after self-administration over 64 days, with buccal pigmentation fading by 28 days after stopping while gingival pigmentation persisted at three months — among the most recent published safety reports [6]. Forensic analyses of products bought online confirm wide variability in identity and content, which means none of these risks can be cleanly separated from contamination [30][31].